Cited by 58Cancer-related Molecular PathwaysGenetic factors in colorectal cancerGenomics and Rare Diseases

Transcriptional functionality of germ line p53 mutants influences cancer phenotype

Open access
Monti, Paola, Ciribilli, Yari, Jordan, Jennifer, Menichini, Paola, Umbach, David M., Resnick, Michael A., Luzzatto, Lucio, Inga, Alberto +1 more·2007·Clinical Cancer Research

Published version of a preprint

Abstract

Purpose The TP53 tumor suppressor gene encodes a sequence-specific transcription factor that is able to transactivate several sets of genes, the promoters of which include appropriate response elements. Although human cancers frequently contain mutated p53, the alleles as well as the clinical expression are often heterogeneous. Germ line mutations of TP53 result in cancer proneness syndromes known as Li-Fraumeni, Li-Fraumeni--like, and nonsyndromic predisposition with or without family history. p53 mutants can be classified as partial deficiency alleles or severe deficiency alleles depending on their ability to transactivate a set of human target sequences, as measured using a standardized yeast-based assay (see http://www.umd.be:2072/index.html). We have investigated the extent to which the functional features of p53 mutant alleles determine clinical features in patients who have inherited these alleles and have developed cancer. Experimental design We retrieved clinical data from the IARC database (see http://www.p53.iarc.fr/Germline.html) for all cancer patients with germ line p53 mutations and applied stringent statistical evaluations to compare the functional classification of p53 alleles with clinical phenotypes. Results Our analyses reveal that partial deficiency alleles are associated with a milder family history (P = 0.007), a lower numbers of tumors (P = 0.007), and a delayed disease onset (median, 31 versus 15 years; P = 0.007) which could be related to distinct tu…

Integrity signals

Registry

Crossref · 10.1158/1078-0432.ccr-06-2545

Cites

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Many tumor-associated p53 mutants exhibit change-of-spectrum transactivation from various p53 targets.

    “Since many tumor-associated p53 mutants exhibit change-of-spectrum transactivation from various p53 targets, we examined the ability of twenty-five p53 mutants to activate endogenous expression of the TLR gene family in p53 null human cancer cell lines following transfection with p53 mutant expression vectors.”

The citation lists haven’t been fetched yet

References 35 · Cited by 58

Authors
Monti, P., Ciribilli, Y., Jordan, J., Menichini, P., Umbach, D. M., Resnick, M. A., Luzzatto, L., Inga, A., & Fronza, G.
Affiliations
  • 1Molecular Mutagenesis Unit, Department of Translational Oncology, National Cancer Research Institute, Genoa, Italy;
  • 2Chromosome Stability Section,
  • National Institutes of Health (US)
  • Tumour Institute of Tuscany (IT)
Venue
Clinical Cancer Research
Published
2007-07-01
Volume
13
Issue
13
Pages
3789-3795
ISSN
  • 1078-0432 (ISSN-L)
  • 1557-3265
OpenAlex
W2165065353
Cited by
58
References
35
Citations by year
2026: 3 · 2025: 3 · 2024: 2 · 2023: 5 · 2022: 1 · 2021: 3 · 2020: 4 · 2019: 2 · 2018: 6 · 2017: 2 · 2016: 4 · 2014: 5 · 2013: 2 · 2012: 2
FWCI
2.02
Type
journal article
Language
en
Open access
Locations
  • Clinical Cancer Research (publishedVersion)
  • PubMed (publishedVersion)
  • Europe PMC (PubMed Central) (acceptedVersion)
  • PubMed Central (acceptedVersion)
  • Institutional Research Information System (Università degli Studi di Trento) (submittedVersion)
Funders
  • National Institutes of Health
  • National Institute of Environmental Health Sciences (Z01ES065079)
Topics
  • Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
  • Health Sciences › Medicine › Pathology and Forensic Medicine › Genetic factors in colorectal cancer
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genomics and Rare Diseases
Keywords
TP53, Li-Fraumeni syndrome, Li-Fraumeni-like syndrome, cancer susceptibility, family history (medicine), tumor number, age of onset, tumor spectrum, clinical phenotype
MeSH terms
Adolescent, Adult, Aged, Child, Humans, Middle Aged, Mutation, Neoplasms, Phenotype, Precancerous Conditions, Transcription, Genetic, Transcriptional Activation, Genes, p53, Tumor Suppressor Protein p53, Germ-Line Mutation

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review